Regulatory approval
Published by the Health Service Executive. Approved
The Republic of Ireland's Health Service Executive (HSE) has approved ivosidenib as a treatment option for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.
This is written in the approval document as:
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | IDH1 p.R132C | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132G | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132H | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-10-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |